Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

• Status: NOT_YET_RECRUITING
• Trial end date: 2030-01-22

Summary

This is a parallel, Phase 2/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype.

Participation to the study consists of 3 periods:

• Screening period of up to 4 weeks
• Randomized intervention period of approximately 48 weeks
• Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.

• Phase: PHASE3

Details

• Lead Sponsor: Sanofi